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Summary:
The aim of this study was to identify trends in high-dose
chemotherapy (HDC) with autologous hematopoietic stem
cell transplantation (ASCT) and to assess survival in a
large cohort of breast cancer (BC) patients receiving this
therapy in Europe from 1990 to 1999. A total of 7471
patients who received HDC with ASCT between January
1, 1990 and December 31, 1999 were reported to the
European Group for Blood and Marrow Transplantation
Registry. Data required for demographics and survival
analysis were available for 2679 patients with high-risk
primary BC; 921 patients with inﬂammatory BC (IBC),
and 2295 patients with metastatic disease. The main
evaluation parameters were progression-free survival
(PFS) and overall survival (OS). Between 1990 and
1998, autotransplants for BC increased 30-fold. Signiﬁ-
cant trends included use of blood-derived rather than
marrow-derived stem cells, increment of reporting centers
and decrease of mortality within 100 days from trans-
plantation. The 5-year PFS and OS probabilities were 53
and 68% for high-risk disease and 42 and 53% for IBC,
respectively. For metastatic disease 5-year PFS and OS
probabilities in the whole cohort were 18 and 27%,
respectively, while for women transplanted in complete
remission the 5-year PFS was 29%. In conclusion, HDC
with ASCT has been increasingly used until 1998 and the
100-day mortality rate has been constantly less than 2%
from 1995 to date. The 5-year survival of high-risk BC is
related to the number of axillary nodes involved at
surgery. Outcome of patients with IBC is encouraging,
suggesting the need for randomized trials. Patients with
metastatic disease responding to pretransplant chemo-
therapy and harboring ER+ tumors have a better
outcome.
Bone Marrow Transplantation (2003) 32, 489–494.
doi:10.1038/sj.bmt.1704153
Keywords: high-dose chemotherapy; stem cell transplan-
tation; breast cancer
Despite improvements in early detection and adjuvant
therapies, breast cancer (BC) remains a leading cause of
cancer death in Western countries. Mortality at 10 years
exceeds 60% for those patients with 10 or more involved
nodes at surgery or large primary tumors, and nearly all
women diagnosed with metastatic BC ultimately die of
their disease.1,2 Nowhere has there been more controversy
in recent years than in the use of high-dose chemotherapy
(HDC) with autologous hematopoietic stem cell transplan-
tation (ASCT) for BC. Early trials of HDC, based on
favorable laboratory and clinical indicators,3,4 initiated in
the early 1980s, suggested that this approach might favorably
affect the course of operable, high-risk primary and meta-
static BC (MBC).5 Phase II studies created positive expecta-
tions among physicians and their patients, to such an
extent that HDC with ASCT also became widely used as
a therapeutic option outside controlled trials. The use of
peripheral blood (PB) cells instead of bone marrow (BM) for
ASCT6,7 signiﬁcantly reduced the morbidity and mortality
related to HDC8,9 and allowed the utilization of this
procedure also outside specialized or academic centers.10
However, after almost two decades of clinical research in
this ﬁeld and thousands of women with BC receiving HDC,
the appropriate role of this approach remains today
uncertain. Most of the randomized trials reported in the
last few years,11–15 although demonstrating the noninfer-
iority of HDC, have failed to show a survival beneﬁt,
although the follow-up was generally short and the number
of patients was in some cases too small to reach the
expected survival beneﬁt.16 In addition, because of the
heterogeneity of intensity and duration of the standard
dose chemotherapy (SDC) in the control arm, the outcomes
of these studies have been quite variable.17 Recently, Berry
et al18 have reported on a large retrospective analysis
comparing survival of 1079 women with metastatic BC
receiving either HDC (Autologous Blood and MarrowReceived 29 October 2002; accepted 9 March 2003
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Transplant Registry of North America, ABMTR) or SDC
(CALGB database), indicating a statistically signiﬁcant
survival advantage for HDC vs SDC.
As a contribution to the ongoing discussion on HDC for
BC we report here the results of this therapeutic approach
in almost 6000 women receiving ASCT at 370 European
Group for Blood and Marrow Transplantation (EBMT)
centers between 1990 and 1999.
Methods
Patients
The EBMT Solid Tumors Registry was set up in 1984 to
collect information regarding patients undergoing HDC
and ASCT in Europe and the Middle East. EBMT centers
are required to send patient data each year to the Central
EBMT Database either directly, or through a National
Registry where it exists. There are two levels of data:
Minimal Essential Data type A (MED A) which are
compulsory and consider major items such as demographic
data, disease classiﬁcation, type of transplant outcomes
and follow-up; and Minimal Essential Data B (MED B)
referring to items sent on a volunteer basis (type of
conditioning or mobilization regimens, complications,
number of cells transplanted, etc). A total of 10 centers
each year are randomly requested to be audited by an
EBMT committee in order to verify the quality of the
reported data and to compare them with the ones of a
general European survey performed yearly on behalf of the
EBMT where only number of patients and type of graft and
disease are requested.19,20 Before starting the present
evaluation regarding the decade 1990–1999, all centres
were recontacted for missing data. Among 7471 BC
patients reported to the EBMT Registry, 5895 were eligible
for this retrospective analysis and represent the body of this
paper. A total 2679 were reported as having high-risk BC,
921 inﬂammatory BC (IBC) and 2295 metastatic disease.
Cases with an incomplete data set have been excluded from
the analysis.
Statistical analysis
Probabilities of 100-day mortality, progression-free survi-
val (PFS) and overall survival (OS) were calculated using
the Kaplan–Meier product limit estimate.21 The log-rank
test was used for comparisons of PFS and survival between
groups.22 OS and PFS rates were measured from the date of
transplant to the date of last follow-up or death and the
date of progression, respectively.
Results
Between January 1, 1990 and December 31, 1999, 7471
patients with BC receiving HDC and HSCT were reported
to the EBMT Registry, which represents 49% of all cases of
solid tumors in the database. Demographics and essential
clinical data are reported in Table 1.
During the decade, the number of ASCT, along with the
number of reporting centers for BC, increased progressively
until 1998 (Table 1) for all disease stages. During the
following years, a rapid decline in the number of ASCT for
BC has been observed, that is, 1115 (32%) in 1999 and
762 (32%) in 2000 (EBMT Solid Tumor Working Party,
annual reports). Between 1992 and 1994, a dramatic shift
toward a widespread use of PB progenitors occurred (19
and 91%, respectively). Transplant-related mortality, that
is, any death not related to the disease occurring within the
ﬁrst 100 days after the graft, declined in the second half of
the decade, to 1–2%.
Owing to the elevated number of phase II studies,
the conditioning regimens employed are quite different
(Tables 2 and 3). The cyclophosphamide/thiotepa/carbo-
platin (STAMP V) or its variants was the most frequently
used schedule in the adjuvant setting, while high-dose
sequential chemotherapy15 or its variants, largely used in
Italy, ranked second. STAMP V was the most frequently
used regimen also in MBC while mitoxantrone/cyclophos-
phamide/melphalan, which is utilized mainly in France,
ranked ﬁrst in IBC. Overall, 25 different regimens in stage
Table 1 Demographics and essential clinical data of BC patients reported to the EBMT registry from 1990 to 1999
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999
Number of cases 54 113 198 344 579 789 1234 1407 1638 1115
No. of reporting centers 18 30 37 58 82 119 153 175 224 184
Median ASCT procedures
per center/year (range)
3 (1–8) 2 (1–16) 4 (1–28) 3 (1–39) 4 (1–49) 4 (1–48) 5 (1–69) 6 (1–45) 4 (1–61) 4 (1–52)
Median patient age (range) 41 (25–53) 42 (26–61) 42 (27–59) 42 (23–67) 43 (23–66) 44 (18–64) 44 (22–70) 45 (21–69) 45 (22–65) 45 (22–66)
Status of BC at Tx
No evidence of disease (adjuvant) 3 19 52 100 175 282 420 523 645 463
Inﬂammatory BC 12 12 29 59 77 121 147 188 159 117
Metastatic BC 29 60 78 137 207 226 408 396 470 284
Source of HSC
Marrow 38 88 138 112 49 19 11 10 16 6
Blood 10 10 32 191 508 749 1203 1378 1575 1030
Marrow and blood 6 15 28 41 18 14 11 12 9 5
Treatment-related mortality within
100 days from ASCT (%)
3 7 4 3 5 1 2 2 1 1
ASCT=autologous stem cell transplantation; BC=breast cancer; Tx=transplant; HSC=hematopoietic stem cells.
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II/III BC, and 29 in stage IV patients, have been reported
among EBMT centers. Interestingly, BCNU-containing
regimens were not a therapeutic option in Europe.
High-risk primary breast cancer
Relevant patient characteristics are reported in Table 2.
Among 1165 patients with fully available data, 35% had
o10 positive axillary nodes, and 54% had X10 positive
nodes. A proportion of cases had been treated for very
high-risk BC, that is, X20 positive nodes (n¼ 130; 11%).
Kaplan–Meier estimates of OS and PFS of the whole
cohort of adjuvant patients and subgroups with different
lymph node involvement are reported in Figure 1. Median
PFS for the whole high-risk group and those with X10
positive nodes were 74 and 69 months (Figure 1 a and b),
respectively; for patients receiving HDC with less than
10 positive nodes, median PFS was not reached (Figure 1b).
In patients with X20 positive nodes at surgery, survival
rates signiﬁcantly dropped (median DFS¼ 37 months)
(Figure 1c). No statistically signiﬁcant difference was
observed in OS and PFS regarding estrogen-receptor
(ER) status (data not shown).
Inflammatory breast cancer
The EBMT BC Registry includes 921 patients with non-
metastatic IBC treated with HDC, which corresponds to a
rather elevated percentage of 25% of all stage II/III
patients when compared to the ABMTR survey. Although
there is no deﬁnitive explanation for these data, the
tendency toward ASCT for this disease has been rather
high in Europe. In fact, several studies in France have
speciﬁcally investigated the role of HDC in IBC. Patient
characteristics and survival rates are shown in Table 2 and
Figure 1d. Median time to progression after transplant was
40 months.
Metastatic breast carcinoma
Characteristics of women who received HSC with ASCT
for MBC are listed in Table 3. A total of 28% of all patients
were given HDC as consolidation after achieving a
complete response (CR) with conventional treatments.
Overall and PFS of the whole cohort of patients are
reported in Figure 2a; median OS and PFS were 31 and
13 months, respectively. Patients receiving HDC with
ASCT in ﬁrst CR had a signiﬁcantly better PFS compared
to those receiving this therapy in partial response,
stable disease or progression (median 25 vs 13 months,
Fig. 2b). Poorer outcomes were associated with ER-
negative tumors (31 vs 43% OS at 5 years ) (Figure 2c)
and a shorter interval between diagnosis and transplant
(data not shown).
Table 2 Autotransplants for stage II and III BC in Europe
1990–1999
High-risk primary BC
Number of patients registered 2683
Median age (range) 46 (18–70)
Number of positive axillary nodes:
o10 408
X10 627
X20 130
ER status
Positive 381
Negative 476
Source of HSC
Marrow 89
Blood 2549
Marrow and blood 28
Conditioning regimen
CTCb or variant 470
HDS 274
C-PAM-M 146
I-Cb-E 49
Others 258
Toxic death rate at day 100 1%
Inﬂammatory breast cancer
Number of patients registered 921
Median age (range) 45 (19–65)
Source of HSC
Marrow 81
Blood 786
Marrow and blood 22
Type of conditioning regimen
CTCb (or variant) 102
C-PAM-M 131
Others 122
Toxic death rate at day 100 2%
ER=estrogen receptor; HSC=hematopoietic stem cells; C=cyclophos-
phamide; T=thiotepa; Cb=carboplatin; HDS=high-dose sequential
chemotherapy; PAM=melphalan; M=mitoxantrone; I=ifosphamide;
E=etoposide.
Table 3 Autotransplants for MBC in Europe 1990–1999
Number of patients registered 2295
Median age (range) 45 (18–69)
ER status
Positive 475
Negative 405
Status of BC at graft:
CR 635
PR 562
SD 477
SR 519
Front line 102
Conditioning regimen
CTCb or variant 392
C-PAM-M 237
I-Cb-E 127
T-PAM 99
Others 343
Toxic death rate at day 100 3%
Interval between diagnosis and transplant
o12 mo 625
X12 mo 1670
MBC=metastatic breast cancer; ER=estrogen receptor; CR=complete
response; PR=partial response; SD=stable disease; SR=sensitive relapse;
C=cyclophosphamide: T=Thiotepa; Cb=carboplatin; PAM=melphalan;
M=mitoxantrone; I=ifosphamide; E=etoposide; mo=months.
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Discussion
As a result of high expectations for the role of HDC as a
treatment for BC, the number of transplants performed in
Europe consistently increased from 1990 to 1998. In more
recent years, the number of procedures has diminished due
to premature reports from randomized trials that did not
show the expected survival advantage in favor of HDC.
Highs and lows in the enthusiasm for HDC in BC has been
largely unreasonable since no deﬁnitive conclusions can be
drawn despite a huge number of studies reported through-
out the last two decades.16,17 This has cast a pall over the
entire ﬁeld and has resulted in both a low accrual of early
prospective trials (irrational exuberance phase) and a
moratorium on new studies (reticence phase).
The EBMT Registry data conﬁrm that HDC with ASCT
today is a safe procedure. Mortality rate within 100 days
from transplantation has signiﬁcantly reduced during the
last decade, possibly related to the use of blood cells as
source of HSC and a widespread better knowledge of the
whole procedure. Moreover, the overall low mortality rate
might also be related to the use of preparative regimens
with a low toxicity proﬁle, that is, the cyclophosphamide/
BCNU/ cisplatin (STAMP I) regimen, which is associated
with a high treatment-related mortality,14 is only anecdo-
tally reported in European surveys.10 It is worth noting that
the switch from BM to PB as the source of stem cells
occurred rapidly in mid-1990s and the reinfusion of BM
plus PB stem cells has been utilized in a minority of patients
in Europe (ie 12% in 1993, 0.25% in 1995) compared to the
higher rate reported in the North American Registry.23 This
might be related to legal issues, which were more stringent
in the US, or possibly to a earlier conﬁdence of European
physicians on the durability of hematopoiesis following
autografting of PB cells.24
The clinical results of our retrospective analysis should
be viewed considering that patients receiving HDC differ
from the general population of women with BC. Thus,
differences observed between patients receiving transplan-
tation and those who received SDC in historical data bases
may result from selection biases. This underscores the
importance of comparing HDC and SDC in comparable
subjects within large randomized trials. Unfortunately, the
outcomes of the phase III studies so far reported had been
quite variable, this partially depending on their hetero-
geneity and the lack of sufﬁcient numbers of patients to
assess interventions with adequate statistical power.15 In
addition, they have been reported in some cases without
Figure 1 Kaplan–Meier estimates of OS and PFS of patients with high-risk primary breast cancer (a: whole cohort; b and c: by lymph node involvement)
and inﬂammatory breast cancer (d).
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sufﬁcient follow-up.11,25 Our retrospective analysis, includ-
ing almost 6000 patients reported in the EBMT Registry,
may be useful in complementing data from these rando-
mized trials. It allows the following clinical considerations.
In the 934 evaluable patients with high-risk primary BC,
deﬁned by extensive axillary node involvement, our data
conﬁrm that survival is related to the number of positive
nodes at surgery, but not to the ER status. Results
presented here cannot be compared with previous reports
of SDC and the controversy about the efﬁcacy of HDC
for high-risk BC remains unsettled. The available results
of six large phase 3 studies,13–15,26–28 only one having been
published in a peer-reviewed journal,13 are still too
preliminary, while in two studies the control arms were
not conventional therapies.13,14
In the 921 patients with IBC, our data suggest an appa-
rent advantage in DFS rates from the inclusion of HDC in
the multidisciplinary management of this disease.29–31
Randomized trials in this subgroup of patients are neces-
sary to evaluate the potential beneﬁts of such a strategy.
In the large cohort of 2230 patients with MBC, women
receiving HDC as consolidation therapy after achieving CR
had the best prognosis, with one out of four patients being
disease-free at 5 years. This result conﬁrms the data from
the ABMTR18,23,32 and suggests that HDC with ASCT may
cure a subset of patients with MBC.33 Despite these
encouraging results, available data from randomized trials
reported to date are contradictory. It is noteworthy that
three trials, 11,12,34 which addressed the value of consolida-
tion with HDC vs SDC in chemosensitive patients, were under-
sized as to the number of patients transplanted in CR. This
aspect seems critical in interpreting their results, as patients
in CR are those who are likely to beneﬁt most from HDC.
In our analysis time to relapse and ER-positive disease were
associated with a better outcome as previously reported.32
Based on the results of this analysis, we recommend
that continued investigation of high-dose strategies is still
necessary. The information presented here, as well as the
maturing of data from large controlled studies should guide
future trials aimed at identifying subsets of patients who
are more likely to beneﬁt from HDC. Further improvement
of HDC with ASCT is likely to come, in the near future,
by integrating HDC with novel treatment strategies with
different and potentially complementary mechanisms of
action.
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